IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+29.45%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$368M
AUM Growth
+$368M
(+0.58%)
Cap. Flow
-$72.5M
Cap. Flow
% of AUM
-19.73%
Top 10 Holdings %
Top 10 Hldgs %
47.34%
Holding
127
New
24
Increased
22
Reduced
26
Closed
20
Top Buys
| 1 |
Corbus Pharmaceuticals
CRBP
|
$14.3M |
| 2 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$10.9M |
| 3 |
Cytokinetics
CYTK
|
$8.07M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$7.7M |
| 5 |
Pyxis Oncology
PYXS
|
$7.08M |
Top Sells
| 1 |
argenx
ARGX
|
$26.5M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$21.2M |
| 3 |
SPDR S&P Homebuilders ETF
XHB
|
$19.1M |
| 4 |
Nuvalent
NUVL
|
$11.8M |
| 5 |
Disc Medicine
IRON
|
$10.6M |
Sector Composition
| 1 | Healthcare | 98.68% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITOS
51
DELISTED
iTeos Therapeutics
ITOS
| $1.38M | 0.15% |
101,325
-245,146
| -71% | -$3.34M |
|
|
ALLK
52
DELISTED
Allakos
ALLK
| $1.18M | 0.13% |
932,675
+695,619
| +293% | +$876K |
|
53
ProQR Therapeutics
PRQR
$256M
| $1.1M | 0.12% |
483,583
+10,958
| +2% | +$24.9K |
|
54
InflaRx
IFRX
$117M
| $1.09M | 0.12% |
704,987
+16,383
| +2% | +$25.2K |
|
55
Acumen Pharmaceuticals
ABOS
$84.2M
| $1.08M | 0.12% |
266,435
-48,830
| -15% | -$198K |
|
56
Roivant Sciences
ROIV
$8.6B
| $1.06M | 0.12% |
100,609
-51,212
| -34% | -$540K |
|
57
Avalo Therapeutics
AVTX
$139M
| $1.01M | 0.11% |
+46,648
| New | +$1.01M |
|
|
TECX
58
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $965K | 0.11% |
754,061
+35,802
| +5% | +$45.8K |
|
59
Amylyx Pharmaceuticals
AMLX
$877M
| $941K | 0.1% |
331,451
-546,049
| -62% | -$1.55M |
|
60
Milestone Pharmaceuticals
MIST
$151M
| $834K | 0.09% |
466,019
+3,191
| +0.7% | +$5.71K |
|
61
Protara Therapeutics
TARA
$125M
| $813K | 0.09% |
202,701
+14,037
| +7% | +$56.3K |
|
62
Kezar Life Sciences
KZR
$28.5M
| $783K | 0.09% |
868,992
+15,601
| +2% | +$14.1K |
|
|
ELEV
63
DELISTED
Elevation Oncology
ELEV
| $760K | 0.08% |
148,089
-1,023,850
| -87% | -$5.25M |
|
|
NYXH
64
Nyxoah
NYXH
$220M
| $684K | 0.08% |
+50,699
| New | +$684K |
|
65
Veru
VERU
$48.5M
| $663K | 0.07% |
+946,382
| New | +$663K |
|
66
Karyopharm Therapeutics
KPTI
$61.4M
| $618K | 0.07% |
409,355
+9,355
| +2% | +$14.1K |
|
67
Terns Pharmaceuticals
TERN
$651M
| $581K | 0.06% |
88,497
-76,983
| -47% | -$505K |
|
68
Immatics
IMTX
$662M
| $519K | 0.06% |
49,415
+384
| +0.8% | +$4.04K |
|
69
Anebulo Pharmaceuticals
ANEB
$101M
| $453K | 0.05% |
157,862
| – | – |
|
70
Tempest Therapeutics
TPST
$46.6M
| $413K | 0.05% |
105,600
| – | – |
|
71
Q32 Bio
QTTB
$20.9M
| $381K | 0.04% |
+22,335
| New | +$381K |
|
|
HOOK
72
DELISTED
HOOKIPA Pharma
HOOK
| $378K | 0.04% |
530,776
| – | – |
|
73
Relmada Therapeutics
RLMD
$48.8M
| $188K | 0.02% |
40,369
| – | – |
|
|
CMMB
74
Chemomab Therapeutics
CMMB
$15.7M
| $166K | 0.02% |
213,392
| – | – |
|
75
Stoke Therapeutics
STOK
$1.08B
| $92K | 0.01% |
6,816
-5,300
| -44% | -$71.6K |
|